The US Food and Drug Administration has approved a new standalone reader device for Abbott’s FreeStyle Libre 3 integrated glucose monitoring system, the company announced on 14 April.
The FreeStyle Libre 3 reader offers an alternative to the FreeStyle Libre smartphone app. It connects to the sensor on the user’s arm and displays glucose readings on a “large,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?